Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors

被引:227
作者
Zaidi, A
Schmoeckel, M
Bhatti, F
Waterworth, P
Tolan, M
Cozzi, E
Chavez, G
Langford, G
Thiru, S
Wallwork, J
White, D
Friend, P [1 ]
机构
[1] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England
[2] Papworth Hosp, Cambridge CB3 8RE, England
[3] Imutran Ltd, Cambridge, England
关键词
D O I
10.1097/00007890-199806270-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In order to circumvent the complement-mediated Hyperacute rejection of discordant xenografts, a colony of pigs transgenic for the human regulator of complement activity, human decay-accelerating factor (hDAF), has been produced, Methods. Seven kidneys from hDAF transgenic pigs and six kidneys from nontransgenic control pigs were transplanted into cynomolgus monkeys; both native kidneys were removed during the same operation, The recipient animals were immunosuppressed with cyclosporine, steroids, and cyclophosphamide. Results. In the transgenic group, the median survival time was 13 days (range, 6-35 days); the median survival time in the control group was 6.5 days (range, 0.3-30 days). There were no cases of hyperacute rejection in the transgenic group, and the two longest-surviving kidneys in this group showed no evidence of rejection ore histological examination, In contrast, all control kidneys underwent antibody-mediated rejection, one demonstrating hyperacute rejection and the others acute vascular rejection, Conclusion. This study demonstrates that (i) a kidney from an hDAF transgenic pig can support the life of a primate for up to 35 days (and also shows the basic physiological compatibility between the pig and nonhuman primate); (ii) nontransgenic kidneys are not routinely hyperacutely rejected; and (iii) the presence of hDAF on the kidney confers some protection against acute vascular rejection. Improved immunosuppression and immunological monitoring may enable extended survival.
引用
收藏
页码:1584 / 1590
页数:7
相关论文
共 43 条
[1]  
ATKINSON J P, 1991, Clinical and Experimental Immunology, V86, P27
[2]   XENOGENEIC TRANSPLANTATION - A REVIEW [J].
AUCHINCLOSS, H .
TRANSPLANTATION, 1988, 46 (01) :1-20
[3]  
CALNE RY, 1970, TRANSPL P, V2, P550
[4]  
Cooper D.K.C., 1991, XENOTRANSPLANTATION, P481
[5]   SPECIFIC INTRAVENOUS CARBOHYDRATE THERAPY - A NEW CONCEPT IN INHIBITING ANTIBODY-MEDIATED REJECTION EXPERIENCE WITH ABO-INCOMPATIBLE CARDIAC ALLOGRAFTING IN THE BABOON [J].
COOPER, DKC ;
YE, Y ;
NIEKRASZ, M ;
KEHOE, M ;
MARTIN, M ;
NEETHLING, FA ;
KOSANKE, S ;
DEBAULT, LE ;
WORSLEY, G ;
ZUHDI, N ;
ORIOL, R ;
ROMANO, E .
TRANSPLANTATION, 1993, 56 (04) :769-777
[6]  
COOPER DKC, 1988, J HEART TRANSPLANT, V7, P238
[7]  
COZZI E, 1994, TRANSPLANT P, V26, P1402
[8]   THE GENERATION OF TRANSGENIC PIGS AS POTENTIAL ORGAN DONORS FOR HUMANS [J].
COZZI, E ;
WHITE, DJG .
NATURE MEDICINE, 1995, 1 (09) :964-966
[9]  
DALMASSO AP, 1992, AM J PATHOL, V140, P1157
[10]   INHIBITION OF COMPLEMENT-MEDIATED ENDOTHELIAL-CELL CYTOTOXICITY BY DECAY-ACCELERATING FACTOR - POTENTIAL FOR PREVENTION OF XENOGRAFT HYPERACUTE REJECTION [J].
DALMASSO, AP ;
VERCELLOTTI, GM ;
PLATT, JL ;
BACH, FH .
TRANSPLANTATION, 1991, 52 (03) :530-533